Pneumonia is the cause of significant morbidity and mortality, despite advances in diagnosis and antibacterial treatment. Pneumonia is often misdiagnosed and mistreated up until recently. Recent classification of pneumonia consists of community-acquired pneumonia, health care-associated pneumonia, hospital-acquired pneumonia, and ventilator-associated pneumonia. The etiology, risk factors, and treatment are different among them. This article briefly introduces new concepts and ideas in biomarkers, diagnosis, treatment, prognosis, and prevention of pneumonia during the past 2 years. One of the most frequent subjects of recent papers was those about pandemic H1N1 in 2009. 
Introduction
Pneumonia is still the leading disease of infectious cause despite many efforts in diminishing of morbidity and mortality. In the past, pneumonia was usually classified as community-acquired (CAP), hospital-acquired (HAP), or ventilator-associated (VAP). Nowadays, a new category of pneumonia-termed health care-associated pneumonia (HCAP) was proposed because some outpatients had potential of multidrug-resistant (MDR) pathogens same as HAP. However, some challenge for this concept for HCAP has emerged. Numerous papers about novel biomarkers, diagnostic technology, classification, antimicrobial agents, treatment, prognosis, and vaccines were published for the past 2 years. In this article, several recent clinical studies about novel biomarkers, prevention and treatment of CAP, epidemiology for HCAP and HAP, and ventilator associated tracheobronchitis (VAT), will be discussed.
Community Acquired Pneumonia (CAP)
CAP is a common and potentially serious illness that is associated with high morbidity and mortality. Only half of the cases had an etiology microorganism identified. Bacteria are the most common identifiable cause, and among them, Streptococcus pneumonia is the single most common bacterium responsible. Antibiotic therapy is usually begun empirically, because the causative organism is not identified in a proportion of patients 1 . Mortality of pneumonia in Korea is about 9.4 persons per 100,000 in 2006, which is the highest among mortality due to infectious diseases 2 .
1. Biomarker 1) Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology. Bello S, et al. 3 Eur Respir J 2012;39:1144-55
Biomarkers are useful in community-acquired pneumonia
(CAP). Recently, midregional (MR) proadrenomedullin
Review (proADM) has been shown to be of potential prognostic use. We sought to determine whether this prognostic role depends on the cause of CAP. We conducted a prospective cohort study of immunocompetent patients with CAP.
Pneumonia Severity Index (PSI) and CURB-65 score (confusion (abbreviated mental test score of ≤8), urea ≥7 mol/L, respiratory rate ≥30 breaths/min, blood pressure ＜90 mmHg systolic or ＜60 mmHg diastolic, and age ≥65 yrs), blood C-reactive protein, procalcitonin, MR-proADM, and microbiological studies were systematically performed.
Patients were grouped as bacterial, viral/atypical and mixed CAP, and were followed up at 30, 90 and 180 days, and 1 yr. We recruited 228 CAP patients. Identification of at least one pathogen was achieved in 155 (68%) patients.
MR-proADM levels closely correlated with increasing severity scores, and showed an important predictive power for complications and short-and long-term mortality (1 yr).
Its addition to PSI and CURB-65 significantly improved their 2) Comments: Clinical severity scores, the Pneumonia Severity Index (PSI) 4 , and CURB-65 score 5 , are the most frequently used tools for evaluating CAP-associated risk of mortality. Traditionally biomarkers of infection for diagnostic and prognostic purposes have widely been used such as white blood cell count and C-reactive protein (CRP) but their prediction of risk in CAP is limited. Recently hormokine such as procalcitonin has increasing evidence for better diagnosis and guiding antibiotic therapy, and assessing severity 6 . Also, MR-proADM has been shown to be potential biomarker to predict severe complication, mortality and risk stratification of clinical scores 7 . In this study by Bello et al. 3 , MR-proADM levels showed considerable prognostic value with/without clinical severity scores such as PSI and CURB-65 independently of etiology of CAP. Although this study didn't show that MR-proADM discriminated the etiology of CAP, ProADM could be used for the identification of patients with a high risk of mortality that be needed a more rapid initiation of appropriate therapy.
Prevention
1) Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. Smith KJ, et al. 2) Comments: Current recommendations by US Advisory Committee on Immunization Practices (ACIP) are for immunization of persons 2 years and older with conditions at increased risk of serious pneumococcal infections and all persons 65 years and older with 23-valent pneumococcal polysaccharide vaccine (PPSV23) 9 . Although most studies show that PPSV23 has at least moderate effectiveness in preventing invasive pneumococcal disease (IPD), its effectiveness in preventing nonbacteremic pneumococcal pneumonia (NPP), which is at least 10 times more common than IPD, appears to be limited. In 2000, 7-valent pneumococcal conjugate vaccine (PCV7) was introduced for routine childhood immunization. In 2010, PCV13 replaced PCV7 for routine childhood immunization. Also PCV13 has recently been approved by the Food and Drug Administration for use among adults aged 50 years and older 10 . However, the effectiveness of PCV13 in preventing NPP in adults is unclear and clinical trials are ongoing. Routine childhood vaccination with PCV13 might have potential further indirect effects in adults. This study by Smith et al. 8 suggests that PCV13 instead of PPSV23 for routine immunization of adults, favor in prevention against pneumococcal disease in an economically reasonable fashion. But they need two assumptions. First, PCV13 would be effective in preventing NPP in adults and secondly herd immunity effect from childhood PCV13 would not been greater. In the future, improvements in vaccines against pneumococci and increased rates of immunization in community will bring reductions in the incidence of pneumococcal disease.
3. Treatment 1) Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomized, double-blind, placebo-controlled trial. Meijvis SC, et al. 11 Lancet 2011;377:2023-30
Background Whether addition of corticosteroids to antibiotic treatment benefits patients with community-acquired pneumonia who are not in intensive care units is unclear.
We aimed to assess eff ect of addition of dexamethasone on length of stay in this group, which might result in earlier resolution of pneumonia through dampening of systemic inflammation.
Methods In our double-blind, placebo-controlled trial, we randomly assigned adults aged 18 years or older with con- 2) Comments: Early diagnosis and rapid initiation of appropriate antibiotics is most important in treatment for CAP 12 .
There are many studies to use corticosteroid in severe pneumonia and sepsis because dexamethasone is lowering of the cytokine response. But recent guideline for sepsis recommend not to use corticosteroids to treat sepsis in the absence of shock unless the patient's endocrine function isn't intact or patients has corticosteroid history 13 . The effect of corticosteroids in addition to antibiotics in patients with CAP who are admitted to general ward is unclear. In this article, the authors suggested the early use of dexamethasone in immunocompetent patients could reduce the length of hospital stay and costs despite increase of hyperglycemia.
Hospital-Acquired Pneumonia (HAP)
HAP, VAP, and HCAP remain important causes of morbidity and mortality despite advances in antimicrobial therapy, better supportive care modalities, and the use of a wide-range of preventive measures. HAP is defined as pneumonia that occurs 48 hours or more after admission, which was not incubating at the time of admission. VAP refers to pneumonia that arises more than 48∼72 hours after endotracheal intubation. HCAP includes any patient who was hospitalized in an acute care hospital for two or more days within 90 days of the infection; resided in a nursing home or long-term care facility; received recent intravenous antibiotic therapy, chemotherapy, or wound care within the past 30 days of the current infection; or attended a hospital or hemodialysis clinic 14 .
Nursing-home-acquired pneumonia in Germany:
an 8-year prospective multicentre study. Ewig S, et al. 15 Conclusions Excess mortality in patients with NHAP cannot be attributed to a different microbial pattern but appears to result from increased comorbidities, and consequently, pneumonia is frequently considered and managed as a terminal event.
1) Comments: NHAP is associated with higher mortality than CAP. Data from the USA showed an excess of MDR pathogens in patients with HCAP and the guideline of HAP in 2005 included HCAP as HAP 14 . But recent studies has revealed this higher mortality rate in HCAP was not related to different etiologies including potential MDR pathogens and inadequate use of initial antibiotics but underlying condition 16 . NHAP is a main subclass of HCAP. Therefore this article by using data from the prospective multicenter Competence Network for Community-acquired pneumonia (CAPNETZ) database in German for hospitalized patients aged ≥65 years with CAP or NHAP for 8 years showed that excess mortality didn't associate with potential multidrug-resistant pathogens but patient's functional status and treatment restriction. Similarly, other article conducted in UK for patients with HCAP revealed that increased mortality was primarily related to patient's underlying factors rather than MDR pathogens 17 . The other European cohort study demonstrated that antibiotic resistance little influenced on the overall effect of HCAP in patients admitted to intensive care unit Conclusion: VAT occurs less commonly than VAP but at a similar incidence in medical and surgical ICU patients.
VAT frequently progressed to VAP, and patients diagnosed with VAT had similar outcomes to those diagnosed with VAP, suggesting that antimicrobial therapy is appropriate for VAT. VAT is also frequently caused by MDR organisms, and this should be taken into account when choosing antimicrobial therapy.
1) Comments:
VAT is a new disease concept as an intermediate condition between bacterial airway colonization and VAP 22 . There is controversy whether VAP is a simple colonization or precursor of VAP. There are not many studies about VAT to define the diagnosis criteria or to characterize its incidence and outcomes. This prospective cohort study defined VAT as the presence of all of the following in a patient intubated with endotracheal tube and receiving mechanical ventilation for ＞48 hours: body temperature ＞38. cfu/mL, and no new or progressive infiltrate on portable chest radiograph. Although incidence of VAT in this study, which was 1.4%, was much lower than that of a previous randomized study where the incidence of VAT was 10.6%, this study by Dallas et al. 21 demonstrated VAT could progress to VAP and further suggested the use of antibiotics treatment and identification of multidrug resistant pathogens in VAT. Further studies are necessary to determine patients with VAT who would need antimicrobial therapy and optimal duration of antibiotic treatment.
Summary
In recent two years, new biomarkers and vaccination were introduced, corticosteroid as adjuvant therapy in non-immnocompromised patients with CAP was favored, and weighed that high mortality of HCAP was not associated MDR pathogens. Concensus on new guidelines for HAP and VAP in Asia and further studies on VAT were suggested.
